To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Mar 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand how T cells, which are a type of immune cell, can help in managing and monitoring advanced epithelial ovarian cancer (EOC). Researchers want to see if changes in the diversity of T cells in the blood can indicate how well treatment is working and if they can predict the chances of cancer coming back. This study aims to provide a non-invasive method to track treatment responses and improve the understanding of cancer outcomes.

To participate in this trial, women aged 18 to 75 who have recently been diagnosed with advanced stages of ovarian cancer (Stage III or IV) may be eligible. Participants should be in good physical shape, as indicated by a score of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, which means they can carry out daily activities with little to no difficulty. Those who join will need to provide blood samples and other medical information throughout their treatment to help researchers gather important data. It’s important to note that certain individuals, such as those who have had specific types of chemotherapy or have certain medical conditions, may not be eligible for this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed patients with advanced EOC, 18-75 years of age: including patients with preoperative assessment of stage III-IV EOC, who underwent initial tumour cytoreduction and 6-8 courses of postoperative chemotherapy with paclitaxel + carboplatin/docetaxel + carboplatin;
• • Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;
• • Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;
• • Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.
• • The initial and follow-up treatment processes are in accordance with NCCN guidelines;
• Exclusion Criteria:
• • Neoadjuvant chemotherapy patients;
• • Splenectomy patients;
• • Patients with contraindications to radiotherapy;
• • Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;
• • Unacceptable or unavailable means of assessing specified efficacy such as imaging;
• • Vaccination within 2 months; antibiotics for infection within 2 weeks; history of blood transfusion within 2 weeks;
• • Long-term use of recombinant human erythropoietin, recombinant human interleukin, Ricodin tablets and other drugs affecting the composition of blood cells;
• • Severe organ dysfunction;
• • Infectious diseases such as immunodeficiency syndrome, active tuberculosis, HIV infection, and other infectious diseases not suitable for participation;
• • Pre-cancerous diseases of the blood, such as myelodysplastic syndromes;
• • Have received immunosuppressive therapy within 2 weeks;
• • Suffering from blood clotting disorders.